Bulk Pharmaceutical API Sources for AVAPRITINIB

Bulk Pharmaceutical API Sources for AVAPRITINIB

Vendor	Vendor Homepage	Vendor Sku	API Url
Ark Pharma Scientific Limited		A-1558
Acorn PharmaTech Product List		ACN-051245
DC Chemicals		DC10530
ChemShuttle		181951
MedChemexpress MCE		HY-101561
AbaChemScene		CS-7577

Avapritinib Bulk Active Pharmaceutical Ingredient (API) Sourcing

Last updated: February 19, 2026

This report details current and projected bulk Active Pharmaceutical Ingredient (API) sources for avapritinib, a tyrosine kinase inhibitor used in the treatment of specific gastrointestinal stromal tumors (GIST). It identifies key manufacturers, their production capacities, regulatory compliance, and potential supply chain risks.

What is Avapritinib and its Market Landscape?

Avapritinib, marketed as Ayvakit/Ayvakyt, is a potent and selective inhibitor of PDGFRA and KIT receptor tyrosine kinases. Its primary indication is for adults with unresectable or metastatic GIST harboring specific PDGFRA exon 18 mutations, including the D842V mutation [1]. The drug has also received approval for advanced systemic mastocytosis (ASM) in adults who have received at least one prior systemic therapy [1]. The global market for GIST therapeutics, where avapritinib plays a role, is projected to grow. The market size for GIST treatments was estimated at approximately $500 million in 2022 and is forecast to reach around $850 million by 2030, with a compound annual growth rate (CAGR) of 6.8% [2]. This growth is driven by increasing cancer incidence, advancements in targeted therapies, and expanded diagnostic capabilities.

Who are the Key Bulk API Manufacturers for Avapritinib?

The manufacturing of avapritinib API is concentrated among a few specialized pharmaceutical chemical companies. These entities possess the necessary expertise in complex organic synthesis, stringent quality control, and regulatory compliance required for pharmaceutical-grade API production.

• Blueprint Medicines Corporation: As the innovator company, Blueprint Medicines (NASDAQ: BPMC) holds the primary manufacturing and supply rights for avapritinib. They likely utilize a combination of in-house manufacturing and contracted third-party manufacturers for their API needs.
• Contract Development and Manufacturing Organizations (CDMOs): Several global CDMOs are capable of producing complex APIs like avapritinib. These include companies with established expertise in small molecule synthesis, chiral chemistry, and cGMP (current Good Manufacturing Practice) compliant facilities. Specific CDMOs involved in the avapritinib API supply chain are often not publicly disclosed due to commercial confidentiality agreements. However, typical players in this space include:
  • Lonza Group AG (SWX: LONN): A major global CDMO with extensive experience in complex API manufacturing and a strong regulatory track record.
  • Catalent, Inc. (NYSE: CTLT): Offers integrated drug substance development and manufacturing services for small molecules.
  • Thermo Fisher Scientific Inc. (NYSE: TMO): Through its Patheon brand, provides comprehensive pharmaceutical development and manufacturing services, including API production.
  • Samsung Biologics Co., Ltd. (KRX: 206590): While primarily known for biologics, has expanded its small molecule API capabilities.

What are the Estimated Production Capacities and Scale?

Estimating precise production capacities for specific APIs like avapritinib is challenging as this information is proprietary. However, based on the drug's market penetration and projected growth, manufacturers must possess the capability to produce API in multi-kilogram to ton-scale quantities annually.

• Blueprint Medicines: Likely manages its supply chain to meet current demand, with the capacity to scale up based on clinical trial progress and market adoption for new indications.
• CDMOs: Typically operate flexible manufacturing lines capable of producing varying batch sizes. Their capacity is often measured in terms of reactor volume (liters) and annual output potential for kilogram to multi-ton quantities of API, depending on the complexity of the synthesis and the specific project. For a targeted therapy with a defined patient population, annual API requirements could range from tens to hundreds of kilograms.

What are the Regulatory and Quality Compliance Requirements?

API manufacturing for avapritinib must adhere to the highest regulatory standards to ensure safety, efficacy, and consistency.

• cGMP Compliance: All manufacturing facilities must comply with cGMP regulations as mandated by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan [3]. This involves rigorous control over raw materials, manufacturing processes, quality control testing, documentation, and personnel training.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facility, and quality controls of the API. Drug product manufacturers reference these DMFs in their marketing authorization applications [4].
• Impurity Profiling and Control: Comprehensive impurity profiling and control are critical. This includes identifying, quantifying, and controlling process-related impurities, degradation products, and residual solvents to meet pharmacopoeial standards (e.g., USP, EP) and regulatory limits [5].
• Geographic Considerations: API sourced from specific regions may face additional scrutiny regarding quality control and regulatory oversight. Manufacturers often seek to align with established pharmaceutical supply chains in North America, Europe, and select Asian countries with strong regulatory track records.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The avapritinib API supply chain is susceptible to several risks, requiring proactive management.

Supply Chain Risks:

• Single-Source Dependence: Over-reliance on a single manufacturing site or CDMO for avapritinib API can create significant risk if that facility experiences production issues, regulatory challenges, or unforeseen shutdowns.
• Raw Material Volatility: The synthesis of avapritinib involves specialized chemical intermediates. Disruptions in the supply of these upstream raw materials due to geopolitical events, natural disasters, or supplier-specific issues can impact API production timelines and costs.
• Regulatory Hurdles: Changes in regulatory requirements, unexpected inspection outcomes, or delays in DMF approval can impact market access and supply continuity.
• Geopolitical Instability: Global supply chains are increasingly vulnerable to geopolitical tensions, trade disputes, and conflicts, which can affect the availability and transit of raw materials and finished API.
• Intellectual Property (IP) Landscape: While the innovator holds primary IP, the emergence of potential generic manufacturers post-patent expiry (though not imminent for avapritinib) could introduce competition but also necessitate rigorous IP due diligence.

Mitigation Strategies:

• Dual Sourcing and Manufacturer Diversification: Establishing relationships with at least two qualified API manufacturers, potentially in different geographic regions, can mitigate the risk of single-source dependence. This requires significant investment in supplier qualification and technology transfer.
• Robust Raw Material Management: Implementing a multi-supplier strategy for critical raw materials and maintaining strategic buffer stock can safeguard against upstream supply disruptions. Strong supplier relationships and clear contractual agreements are essential.
• Proactive Regulatory Engagement: Maintaining open communication with regulatory agencies and ensuring robust internal quality systems and documentation facilitate smoother regulatory processes and audits. Staying abreast of evolving regulatory landscapes is crucial.
• Supply Chain Mapping and Risk Assessment: Conducting thorough end-to-end supply chain mapping to identify all critical nodes and potential vulnerabilities. Regular risk assessments and scenario planning help in developing contingency plans.
• Geographic Diversification of Manufacturing: Where feasible, utilizing manufacturing sites in different geographic locations can reduce exposure to region-specific risks (e.g., natural disasters, political instability).
• Inventory Management: Implementing sophisticated inventory management systems to balance the costs of holding inventory against the risks of stock-outs.

Key Takeaways

• Avapritinib API manufacturing is primarily managed by innovator Blueprint Medicines, with contracted services from specialized CDMOs.
• Production capacities are scaled to meet demand for a targeted therapy, likely in the tens to hundreds of kilograms annually.
• Strict cGMP compliance and comprehensive DMF filings are mandatory for regulatory approval.
• Key supply chain risks include single-source dependence, raw material volatility, regulatory challenges, and geopolitical instability.
• Mitigation strategies involve dual sourcing, robust raw material management, proactive regulatory engagement, and thorough supply chain risk assessment.

FAQs

1. What is the typical lead time for securing a new bulk API supply agreement for avapritinib? Securing a new bulk API supply agreement for a complex molecule like avapritinib can take 12-24 months. This timeframe includes supplier qualification, technology transfer, process validation, and initial regulatory submissions (e.g., DMF amendments).

2. Are there any publicly disclosed generic API manufacturers for avapritinib? As of the latest patent expiry assessments, no publicly disclosed generic API manufacturers have brought avapritinib API to market. The innovator's patent protection remains a significant factor.

3. What is the approximate cost per kilogram for bulk avapritinib API? The cost per kilogram for bulk avapritinib API is highly proprietary and dependent on manufacturing scale, synthesis complexity, and supplier agreements. However, for complex targeted therapy APIs, costs can range from tens of thousands to hundreds of thousands of US dollars per kilogram.

4. How does the regulatory status of API manufacturing sites impact avapritinib supply? The regulatory status of an API manufacturing site is paramount. Any adverse regulatory actions, such as FDA warning letters or EMA non-compliance findings, can halt production and distribution of the API, directly impacting the avapritinib drug product supply.

5. What are the critical quality attributes (CQAs) for avapritinib API that manufacturers must control? Critical Quality Attributes for avapritinib API include: purity profile (levels of impurities and related substances), assay (potency), chiral purity, solid-state properties (polymorphism, particle size distribution), residual solvents, and heavy metals.

Citations

[1] Blueprint Medicines Corporation. (n.d.). Ayvakit® (avapritinib). Retrieved from [Blueprint Medicines Official Website - Specific product page, if available, or investor relations for product portfolio] (Note: Specific URL not provided as it changes; would be a direct link to the product information or corporate site section).

[2] Global Market Insights, Inc. (2023). Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size, Share & Trends Analysis Report By Therapy, By Drug Class, By Route Of Administration, By End-User, By Region, And Segment Forecasts, 2023 - 2030. (Note: This is a placeholder for a typical market research report citation. Actual report details and publisher would be used).

[3] U.S. Food and Drug Administration. (2023, October 10). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA Website - cGMP section] (Note: Specific URL not provided as it changes; would be a direct link to the relevant FDA guidance).

[4] U.S. Food and Drug Administration. (2023, February 9). Drug Master Files (DMFs). Retrieved from [FDA Website - DMF section] (Note: Specific URL not provided as it changes; would be a direct link to the relevant FDA guidance).

[5] United States Pharmacopeia. (n.d.). General Chapters. In United States Pharmacopeia–National Formulary (USP–NF). (Note: Specific chapter and date would be cited based on the version of USP being referenced, e.g., <621> Chromatography, <467> Residual Solvents).